Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00145002
Status:
COMPLETED
Last Update Posted:
2016-09-22
First Post:
2005-09-01
Brief Title:
A Study for Aggressive Adult T-cell Leukemia-lymphoma ATLL
Sponsor:
Japan Clinical Oncology Group
Organization:
Japan Clinical Oncology Group
Study Overview
Official Title:
Phase III Study of VCAP-AMP-VECP vs Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma ATLL Japan Clinical Oncology Group Study JCOG9801
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit
Detailed Description:
Nothing to describe
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| C000000066 | None | None | None |